These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 36583451

  • 1. Autocrine EGF and TGF-α promote primary and acquired resistance to ALK/c-Met kinase inhibitors in non-small-cell lung cancer.
    Wang Y, Zhang Y, Chen R, Tian X.
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01047. PubMed ID: 36583451
    [Abstract] [Full Text] [Related]

  • 2. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
    Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K.
    Clin Cancer Res; 2012 Nov 15; 18(22):6219-26. PubMed ID: 22843788
    [Abstract] [Full Text] [Related]

  • 3. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
    Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA.
    Cancer Res; 2011 Sep 15; 71(18):6051-60. PubMed ID: 21791641
    [Abstract] [Full Text] [Related]

  • 4. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S.
    Clin Cancer Res; 2012 Jul 01; 18(13):3592-602. PubMed ID: 22553343
    [Abstract] [Full Text] [Related]

  • 5. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 01; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 6. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K.
    Cancer Sci; 2018 Oct 01; 109(10):3149-3158. PubMed ID: 30053332
    [Abstract] [Full Text] [Related]

  • 7. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
    Xu Y, Zhang F, Pan X, Wang G, Zhu L, Zhang J, Wen D, Lu S.
    Cancer Commun (Lond); 2018 May 09; 38(1):19. PubMed ID: 29764505
    [Abstract] [Full Text] [Related]

  • 8. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
    Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS.
    Mol Cancer Ther; 2007 Oct 09; 6(10):2652-63. PubMed ID: 17913856
    [Abstract] [Full Text] [Related]

  • 9. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH, Grauslund M, Urbanska EM, Melchior LC, Rask CK, Costa JC, Skov BG, Sørensen JB, Santoni-Rugiu E.
    BMC Res Notes; 2013 Nov 26; 6():489. PubMed ID: 24279718
    [Abstract] [Full Text] [Related]

  • 10. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
    Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS.
    Cancer Res Treat; 2019 Jul 26; 51(3):951-962. PubMed ID: 30309221
    [Abstract] [Full Text] [Related]

  • 11. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B, de Langen AJ, Hashemi S, Monkhorst K, Rosenberg EH, Heideman DAM, Radonic T, Smit EF.
    Lung Cancer; 2018 Oct 26; 124():130-134. PubMed ID: 30268451
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
    Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR.
    Clin Cancer Res; 2012 Mar 01; 18(5):1472-82. PubMed ID: 22235099
    [Abstract] [Full Text] [Related]

  • 13. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 01; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 14. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.
    McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J.
    Cancer Res; 2010 Feb 15; 70(4):1625-34. PubMed ID: 20124471
    [Abstract] [Full Text] [Related]

  • 15. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
    Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM, Prutisto-Chang K, Oh A, Adams NA, Yeap BY, Chin E, Do A, Marble HD, Stevens SE, Digumarthy SR, Saxena A, Nagy RJ, Benes CH, Azzoli CG, Lawrence MS, Gainor JF, Shaw AT, Hata AN.
    Clin Cancer Res; 2020 Jun 01; 26(11):2535-2545. PubMed ID: 32086345
    [Abstract] [Full Text] [Related]

  • 16. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.
    Int J Oncol; 2015 Mar 01; 46(3):1025-30. PubMed ID: 25502629
    [Abstract] [Full Text] [Related]

  • 17. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
    Ren KH, Qin WW, Wang Y, Peng JC, Hu WX.
    Ann Palliat Med; 2022 Jul 01; 11(7):2503-2509. PubMed ID: 35927783
    [Abstract] [Full Text] [Related]

  • 18. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, Park BM, Park E, Bae JH, Choi CM, Lee JC.
    Cancer Res; 2014 Jan 01; 74(1):253-62. PubMed ID: 24165158
    [Abstract] [Full Text] [Related]

  • 19. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, Wei YF, Lee KY, Tseng YH, Su J, Chung HP, Lin CB, Ku WH, Chiang TS, Chiu CH, Shih JY.
    Eur J Cancer; 2021 Oct 01; 156():1-11. PubMed ID: 34392186
    [Abstract] [Full Text] [Related]

  • 20. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.
    EBioMedicine; 2016 Jan 01; 3():54-66. PubMed ID: 26870817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.